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The yellow fever virus (YFV), the first proven human-pathogenic virus, although isolated in 1927, is still 
a major public health problem, especially in West Africa where it causes outbreaks every year. 
Nevertheless, little is known about its genetic diversity and evolutionary dynamics, mainly due to a 
limited number of genomic sequences from wild virus isolates. In this study, we analyzed the 
phylogenetic relationships of 24 full-length genomes from YFV strains isolated between 1973 and 
2005 in a sylvatic context of West Africa, including 14 isolates that had previously not been 
sequenced. By this, we confirmed genetic variability within one genotype by the identification of 
various YF lineages circulating in West Africa. Further analyses of the biological properties of these 
lineages revealed differential growth behavior in human liver and insect cells, correlating with the 
source of isolation and suggesting host adaptation. For one lineage, repeatedly isolated in a context of 
vertical transmission, specific characteristics in the growth behavior and unique mutations of the viral 
genome were observed and deserve further investigation to gain insight into mechanisms involved in 
YFV emergence and maintenance in nature.  
 
Introduction 
Yellow fever virus (YFV) is the prototype of the genus Flavivirus of the family Flaviviridae and causes 
yellow fever (YF) disease. In human infections, the symptoms range from asymptomatic or mild 
characteristics to a hemorrhagic syndrome that can potentially lead to a fatal outcome with organ 
failure. To date, no specific therapy is available for YF, but a vaccine has been used for many years 
for the prevention and control of epidemics (1, 2). Despite the effectiveness of the live attenuated 
vaccine YFV-17D, the World Health Organization (WHO) estimates that 200,000 cases and 30,000 
deaths occur annually, mostly in Africa (3).  
Over the last 30 years, a major increase of YF infections has occurred due to factors such as low 
vaccination coverage, urbanization, migration of the human population, reinfestation of Aedes aegypti, 
and improved surveillance (4, 5). In 2005, this led to the “YF initiative” supported by the Global 
Alliance of Vaccine and Immunization (GAVI), focusing on controlling YF by combining preventive or 
reactive mass vaccination campaigns with routine immunization. This is realized through an expanded 
program of immunization in an integrated strategy involving reinforced surveillance of YF and adverse 
events following immunizations (AEFI) and the management of vaccine supply targeting countries at 
high risk of YF in West Africa.  
The yellow fever virus is transmitted to nonhuman primates in the sylvatic cycle by mosquitoes of the 
genera Aedes in Africa and Haemagogus in South America. Humans can be infected when they enter 
areas of endemicity and can then introduce the virus into cities, where it can contribute to the 
development of epidemics in the presence of the urban vector Aedes aegypti (4, 6).  
During dry seasons, YFV can survive through vertical transmission from infected female mosquitoes to 
their eggs, wherein the viral particles are stable for long periods and can be reactivated when the 
progeny emerges under better conditions (4, 7).  
The incidence of yellow fever depends on the circulation of the mosquito vector and is therefore 
restricted to the tropical regions of Africa and South America. Surprisingly, YF is absent from Asia, 
although the epidemic vector Aedes aegypti is present in these regions. Hypotheses about a lower 
vector competence of the mosquito strains in Asia or a cross-protective immunity of the population due 
to the presence of other flaviviruses have been debated, but a definite explanation could not be found 
to date (4, 8, 9).  
YFV probably originated in Central Africa, spread subsequently to East and West Africa, and was 
introduced into the Americas with the slave trade between the 16th and 19th centuries (3, 4).  
To date, 7 YFV genotypes have been described (3, 4, 10–12), including 2 in South America and 5 in 
Africa, namely, West Africa genotype I (Nigeria, Cameroon, and Gabon), West Africa genotype II 
(Senegal, Guinea, Ivory Coast, and Ghana), East and Central African genotype (Sudan, Ethiopia, 
Central African Republic, and Democratic Republic of Congo), East African genotype (Kenya), and 
Angola genotype (Angola).  
Most of the phylogenetic studies on YFV used partial sequences of the viral genome (3, 11, 13–16), 
and the number of complete genome sequences is very limited, especially for wild isolates from an 
African sylvatic context. Therefore, more sampling and full-length genome sequencing of sylvatic 
strains are needed to extend our knowledge about the molecular evolution of YFV and could possibly 
identify new genotypes.  
The nucleotide variability among the different genotypes ranges from 25 to 30%, whereas sequence 
homology within one genotype can be very high even if isolations occurred decades apart, suggesting 
a very slow evolution rate and a genetic stability of the virus (3, 11, 14, 17).  
Interestingly, the incidence of YF outbreaks is not uniform within areas of endemicity. Most of the 
outbreaks take place in West Africa, whereas outbreaks in East Africa are rather uncommon. The 
reason for this could possibly be found in the genetic variability that, consequently, could affect the 
virulence of the virus. Indeed, the West African genotype I shows a higher heterogeneity than the 
West African genotype II or the East/Central African genotype (11) and could point to a stronger 
evolutionary activity. In addition, the 3′-nontranslated region (3′-NTR) of the YF viral genome, which 
contains repeated sequences differing among the genotypes by their numbers of iterations, seems to 
play an important role in the replication of the virus and hence could have a great impact on virulence 
(16).  
Besides the intrinsic properties of the virus, factors such as host adaptation and vector and host 
behavior (e.g., movement of populations), as well as climatic and ecological factors, can influence the 
outcome of an infection. These relationships are complex and raise challenges to investigate the 
epidemiology and mechanisms in YF emergence and maintenance in nature.  
A recent study on molecular evolution of YFV, focusing on sylvatic strains in West Africa (15), showed 
that (i) 6 different lineages could be identified within Senegal, emphasizing the diversity of YFV 
circulating in the sylvatic context, (ii) one can speculate that forests such as the Kedougou region 
could play a role of key reservoir of YFV lineages, generating outbreaks from time to time, and (iii) one 
specific lineage (lineage 3) seems to be associated with vertical transmission of the virus in nature, 
raising the question of the impact of genetic diversity on the maintenance mechanism of YFV.  
In this context, we analyzed the full-length genome sequences of the different lineages circulating in 
Senegal and West Africa and investigated their biological properties in insect and human liver cells. 
Using other YFV sequences from GenBank, we performed phylogenetic analyses based on the 
complete genome of the virus.  
 
Materials and Methods 
Virus strains.Virus strains analyzed in this study were provided by the Institut Pasteur de Dakar, WHO 
Collaborating Center for arboviruses and viral hemorrhagic viruses (CRORA) in Senegal, and the 
Robert Koch Institute in Germany (Table 1).  
Cell lines. Two cell lines have been used for virus cultivation and growth kinetics. Ap61 cells (Aedes 
pseudocutellaris) were grown in L15 (Leibovitz) medium (10% fetal calf serum [FCS], 1% penicillin-
streptomycin, 1% glutamine, 10% tryptose phosphate, and 0.05% amphotericin B [Fungizone]) and 
incubated at 28°C without CO2. HepG2 cells (human hepatocellular carcinoma) were grown in RPMI 
medium (10% FCS, 1% penicillin-streptomycin, and 1% glutamine) at 37°C with the addition of 5% 
CO2.  
Virus cultivation. All virus stocks used for the kinetic experiments were produced on Ap61 cells. Cells 
were grown in cell culture flasks (75 cm
2
) until they reached a confluence of approximately 70%. The 
medium was discarded, and 500 μl filtered sterile virus solution was added to the cells. The flasks 
were gently agitated every 10 min during incubation to enhance viral infection. After 1 h, 15 ml L15 
medium (2% FCS, 5% tryptose phosphate, 1% glutamine, 1% penicillin-streptomycin, and 0.05% 
amphotericin B) was added, and the infected cells were incubated for 8 days until a cytopathic effect 
was observable. The status of infection was tested by real-time PCR, immunofluorescence assay 
(IFA), and plaque assay. Supernatants were frozen at −80°C for further experiments.  
Growth kinetics. The growth kinetics were performed in 12-well plates using one plate per virus strain 
and one uninfected plate as a negative control. Each well was seeded with 2.4 × 10
5
 cells in a volume 
of 400 μl of the appropriate medium with 5% FCS and infected with another 400 μl virus solution, 
resulting in a multiplicity of infection (MOI) of approximately 0.01 (equates to 2.4 × 10
3
 PFU/well). After 
an incubation time of 4 h, the medium was removed and replaced with 2 ml of new medium to set a 
zero point for the growth curves. The harvesting of one well occurred immediately before and after the 
change of the infection medium and at 22, 28, 50, 75, 99, 124, and 146 h postinfection. Each harvest 
was performed as follows. Supernatants were removed and frozen at −80°C in small aliquots. Cells 
were washed once with phosphate-buffered saline (PBS) and then removed in 500 μl PBS. One drop 
of this solution was dried on a glass slide for a subsequent immunofluorescence assay. The residual 
250 μl of cells was centrifuged for 5 min at maximum speed, resuspended in 350 μl of RLT buffer plus 
β-mercaptoethanol (RNeasy minikit; Qiagen), and frozen at −80°C for RNA extraction.  
Plaque assay. To determine the amount of infectious viral particles (PFU), 6 × 10
5
 PS cells (porcine 
kidney epithelial cells) in 200 μl L15 medium (5% FCS, 1% penicillin-streptomycin, and 1% glutamine) 





 were added to the wells, also in a volume of 200 μl L15 medium. After an 
incubation period of approximately 4 h, the cells were covered with 400 μl overlay medium (L15 plus 
5% FCS, 1% penicillin-streptomycin, 1% glutamine, and 1.6% carboxylmethyl cellulose) and incubated 
again for 4 (YFV strains 17D and Asibi) or 7 (mosquito isolates) days at 37°C without the addition of 
CO2. Afterwards, the cells were fixed for 15 min with 3.7% formaldehyde and stained for at least 30 
min with naphthol black solution (1 g naphthol blue black, 13.6 g sodium acetate, and 60 ml glacial 
acetic acid per 1 liter H2O). Considering the most appropriate viral dilution, infected cells were visible 
as plaques and calculation of PFU per ml was carried out according to Ferguson and Heath (18).  
Immunofluorescence assay.Cells were dissolved in PBS and dropped on a glass slide. After complete 
drying, cells were fixed for at least 10 min in cold acetone, dried again, and then stored at −20°C until 
staining. Staining was done with a YFV-specific monoclonal mouse anti-E-protein antibody (MAK 
6330) (19) diluted 1:100 in PBS and incubated 1 h at 37°C. After washing three times with PBS, cells 
were incubated with the second antibody (goat anti-mouse IgG, fluorescein isothiocyanate [FITC] 
conjugated; Dianova), diluted 1:200 in PBS, for 1 h at 37°C in the dark. The cells were washed again 
three times with PBS, dried, and covered with ProLong Gold antifade reagent with 4′,6-diamidino-2-
phenylindole (DAPI) (Invitrogen). After dehydration, examination was done by fluorescence 
microscopy (Biozero microscope; Keyence).  
RNA extraction and real-time PCR.Extraction of viral RNA from cell culture supernatants was 
performed with the QIAamp viral RNA minikit (Qiagen) according to manufacturer's instructions. For 
RNA extraction from the cell fraction, cells were lysed in RLT buffer plus β-mercaptoethanol (RNeasy 
minikit; Qiagen) and homogenized using the QIAshredder columns from Qiagen. Further purification of 
the RNA was done according to the protocol of the RNeasy minikit (Qiagen).  
For the detection and quantification of viral RNA, a YFV-specific real-time assay was applied as 
described previously (20).  
Full-length genome sequencing.For the full-length genome sequencing, viral RNA was extracted from 
the supernatants of YFV-infected Ap61 cells using the QIAamp viral RNA minikit (Qiagen). cDNA 
synthesis, PCR, and sequencing were done as described elsewhere (21, 22).  
Phylogenetic analyses.The whole genome sequences of 24 YFV strains and one Sepik virus strain 
(Tables 1 and 2) serving as an outgroup were aligned using the muscle alignment tool implemented in 
Geneious Pro version 5.4.3 (Biomatters Ltd.).  
The phylogenetic analyses were performed with the Bayesian and maximum likelihood (ML) methods. 
Model selection and the Bayesian analyses were performed as described previously using the 
programs jModelTest and Mr Bayes 3.1.2 (22, 23). The ML analyses were carried out using the 
program SeaView version 4.3.5 (http://pbil.univ-lyon1.fr/software/seaview.html) (24). For this analysis, 
a general time-reversible model plus gamma distribution (GTR+G model) was selected according to 
the jModelTest analysis and further settings were left at default values. This analysis was performed 
with 1,000 bootstraps. The resulting Bayesian and ML consensus trees were visualized with the 
software FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/software/figtree). Trees were rooted to the 
outgroup Sepik virus, and to ensure visual clarity, the branches were transformed to a cladogram 
style.  
Nucleotide sequence accession numbers.All full genome sequences generated in this work have been 
submitted to the GenBank database under accession numbers JX898868 to JX898881.  
 
Results 
Full-length genome sequencing.In this study, 14 YFV isolates were completely sequenced and 
included 9 representatives of the different lineages (except lineage 2) circulating in the sylvatic context 
of Kedougou that have already been sequenced partially (15). Furthermore, 5 new YFV strains (6857, 
6858, 6865, 6866, and 6867), isolated from mosquitoes during the sylvatic amplification in Kedougou 
in 2005, have been sequenced completely (Table 1). Overall, full genome sequences could be 
obtained for all chosen YF strains.  
Two positions of nucleotide variants with effects on the protein level could be identified, presumably 
reflecting heterogeneity in the virus population. The first one is a “Y” at nucleotide position 1140 (E 
protein, amino acid [aa] 56) of strain 357, leading either to the amino acid alanine or valine. The 
second is an “R” at nucleotide position 1376 (E protein, aa 135) of strains 6857, 6858, 6865, 6866, 
and 6867, forming the amino acid isoleucine or valine (Figure 1).  
Considering the comparison of the protein sequence throughout the viral open reading frame (ORF), 
the differences clearly reflect the diverse YF lineages (Figure 1). For lineage 1, only one strain was 
available for sequencing, and thus it appears here as a single isolate. The strains belonging to lineage 
4 (strain 357 compared to the strains isolated in 2005, classified as L4) differ the most among each 
other by 0.41%, whereas the strains of lineages 5 and 6 show variances of only 0.18% and 0.26%, 
respectively. Lineage 3 shows 100% identity among the sequenced strains 333 and 335 at the amino 
acid level. Also, the YFV strains isolated in 2005 in the Kedougou region (6857, 6858, 6865, 6866, 
and 6867) exhibited the same sequence, even though they were isolated from three different mosquito 
vectors (Table 1), and were identified as lineage 4 by phylogenetic analyses (Figure 2). Considering 
only the alignment of the E protein region, we found a variability of 1% for lineage 4, 0.4% for lineage 
5, and 0% for lineages 6 and 3.  
Compared to the reference strain Asibi, variability among amino acids varies between 0.53% for 
lineage 4 and 1.08% for lineage 1 (Table 3). However, closer examination of the mutations 
representing unique features of each lineage (which are defined as the number of mutations that are 
unique to this lineage/total number of differences in this lineage compared to the Asibi strain) reveals 
that discrepancies between the lineages are huge. While the amount of unique features ranges from 
5.5 to 22% for lineages 4, 5, and 6, lineage 1 exhibits unique characteristics of 56.8% and lineage 3 of 
90%. Most of these unique mutations for lineage 3 are located in the E, NS4B, and NS5 proteins 
(Table 3).  
It is noteworthy that strain 307 (lineage 1, Ivory Coast 1973) has an insertion just after the stop codon 
in the 3′-NTR (nucleotide position 3, counted from the beginning of the stop codon of the viral 
polyprotein) and a deletion at position 174. The latter mutation was previously described for strain 85-
82H, isolated in Ivory Coast in 1982, but the insertion was found at position 304 in this case (25). Apart 
from the deviating insertion, strain 307 exhibits a similar sequence in the 3′-NTR as strain 85-82H.  
The strains of lineage 3 show unique mutations at four positions in the 3′-NTR that distinguish them 
from the other strains (7, 8, 54, and 449, counted from the beginning of the stop codon of the viral 
polyprotein). The alignment of the whole 3′-NTR of all sequenced YFV strains is shown in Figure 3.  
Phylogeny of YFV isolates from West Africa. A total of 24 YFV full genomes have been used for 
phylogenetic analyses (Tables 1 and 2). The phylogenetic tree from the ML analysis was consistent 
with the tree that was obtained by Bayesian analysis regarding its topology. Figure 2 shows the 
consensus tree of the Bayesian analysis performed with 10 million generations.  
The obtained consensus tree basically shows a clustering in the same subgroups as the phylogenetic 
tree based on E protein sequences (15). The East and Central African genotypes are clearly 
separated from the West African genotypes (Figure 2). In previous studies, the East and Central 
African strains Couma, Uganda, and Angola were considered independent genotypes (3, 11, 12) but 
appear here in one clade. This may be due to the limited numbers of complete genome sequences 
available for this study.  
The West African genotypes show a clustering into the different lineages described previously. One 
clade represents lineage 1 and is composed of two strains from Ivory Coast. The second clade is 
composed of the wild-type reference strains Asibi and French viscerotropic virus, isolated for the first 
time in 1927 from YF patients in West Africa (26). Clade 3 contains the Senegalese lineage 3 and the 
strain Trinidad79A, representing the only full genome sequence coming from South America. The 
fourth clade within the West African genotypes represents lineage 4 and contains the newly 
sequenced YF strains 6857, 6858, 6865, 6866, and 6867. They are identical in their nucleotide 
sequences and represent only one single virus strain (see above); hence, they appear as a polytomy 
in our tree. Clade 5 contains the strains belonging to lineage 5 together with a strain from Gambia, and 
clade 6 represents lineage 6 including another strain isolated in Ivory Coast.  
Growth kinetics. In order to investigate whether the diversity of YFV has an impact on its biological 
properties, growth kinetics of the different lineages were determined in mosquito (Ap61) and human 
liver cells (HepG2) to reflect the natural hosts (insect vector and primate). Hence, strains 333, 357, 
345, 314, and 307 were tested as representatives of the different YF lineages circulating in West 
Africa (Table 1; lineage 2 was not at our disposal), while the 17D vaccine and the wild-type strain Asibi 
were used as controls.  
The status of infection was visualized by immunofluorescence staining of the cells and quantitative 
reverse transcriptase PCR (qRT-PCR) of RNA equivalents isolated from supernatants and cells. 
Additionally, we determined the amount of infectious viral particles (PFU/ml) from the supernatant 
fraction by plaque assay. The experiments were duplicated in order to confirm the growth behavior of 
the different virus strains and analyzed regarding genome equivalents in cell supernatants. Range 
values of these two approaches are depicted in the corresponding data curves in Figure 4 (see also 
Figure 6 and 7).  
In Figure 4, all tested parameters are shown for the strains Asibi, 357 (lineage 4), and 333 (lineage 3). 
In Figure 4a, the Asibi strain clearly shows better replication in HepG2 cells than in Ap61 cells by 
reaching titers up to 3 logs higher in a period of 2 to 4 days after infection. Nevertheless, nearly 
equivalent titers are obtained in both cell lines after 6 days. After 1 week, the growth curves from Ap61 
cells are still increasing, whereas growth in HepG2 cells is already decreasing after 100 h. This is 
consistent with the result of the immunofluorescence assay (IFA), showing cells dying after 99 h in 
HepG2 cells. Ap61 cells are stable until the end of the experiment when infected with YFV Asibi 
(Figure 5).  
Strain 357 (Figure 4b) shows similar growth in both cell lines, as growth curves are stagnating or 
decreasing after 100 h. In contrast to the reference strain Asibi, HepG2 cells remain stable throughout 
the experiment when infected with strain 357, whereas Ap61 cells started dying after 124 h (Figure 5, 
IFA).  
For strain 333 (Figure 4c), we observed significant differences in the growth curves of the two cell 
lines. In HepG2 cells, the growth of strain 333 is comparable to the YFV reference strains. In Ap61 
cells, nearly no replication activity was detectable by PCR or plaque assay. Likewise, no clear infection 
was visible by IFA (Table 4), although we could observe the early stages of cell death 24 h after 
infection.  
In terms of growth behavior, the replication rate of all YF strains in HepG2 cells is comparable 
regarding the quantity of RNA copies and PFU (Figure 6). Differences are only visible by microscopic 
observation and IFA. In fact, the reference strains Asibi and 17D, as well as strain 333 (lineage 3), 
affect the cells after only 4 days of cultivation (Figure 5, shown for YFV Asibi), whereas strains 345, 
314, and 307 (lineages 5, 6, and 1) kill the cells more slowly from the beginning of day 5 (data not 
shown). Strain 357 (lineage 4) had no major effect on the cells throughout the experiment (Figure 5).  
The Ap61 cellular environment elucidated more differences between the strains. First, the reference 
strains Asibi and 17D exhibit the same growth behavior, but their maximum titers during this 
experiment were lower than those for strains 307, 314, 345, and 357 (Figure 7). Another distinction 
between the reference strains and the mosquito isolates can be seen in the cell uptake (Figure 7b). 
Shortly after infection, RNA copies were undetectable in the cell fraction infected with 17D and Asibi, 
whereas in all other strains, RNA copies were already detectable. The curve progression of the virus 
titer for the reference strains is still increasing at the end of the experiment, which can also be 
demonstrated by IFA (Fig. 5, strain Asibi; Table 4), where cells are still in good condition and not yet 
completely infected after 146 h. The curve progression for the other strains (except strain 333) is either 
stagnating or regressing. This process is also supported by IFA, where cell death is visible after 124 h 
for strains 357, 314, and 307 and after only 76 h for strain 345 (Figure 5, strain 357). Strain 333, 
representing lineage 3, stands out from the other strains regarding the progression of the growth 
curve. The cell uptake seems to be similar to that of the other mosquito isolates (reflected by 
intracellular RNA in Figure 7b), but there is no clear increase of the titer showing replication activity in 
Ap61 cells (Figure 4c and 7). Although we could observe the beginning of cell death 24 h 
postinfection, the IFA remained negative (Table 4).  
Comparing the growth behavior between the two cell lines, strains 307, 357, 345, and 314 (belonging 
to lineages 1, 4, 5, and 6, respectively) show similar growth curves regarding the number of RNA 
copies and infectious particles (Figure 6 and 7), but when considering IFA results, Ap61 cells seem to 
be much more affected than HepG2 cells (Figure 5, strain 357).  
The reference strains Asibi and 17D replicate much better and generate higher titers in HepG2 cells 
and induce cell death in HepG2 cells much faster than in Ap61 cells (Figure 5). Their growth in Ap61 
cells is much slower and seems to occur concurrently with a poor uptake in the cells (Figure 7b). Even 
though 17D is the attenuated vaccine strain of YFV Asibi, and Asibi a wild-type virus, both strains 
show the same growth progression in these experiments.  
Strain 333 (lineage 3) seems not to replicate effectively in Ap61 cells (Figure 4c and 7). In HepG2 
cells, this strain shows the same growth curves for RNA copies and infectious viral particles as the 
other mosquito isolates, but it damages the cells much faster, showing a comparable picture to the 
one presented by the reference strains.  
 
Discussion 
Sequence analysis. Here we provide a total of 14 new full genome sequences from West African YFV 
isolates, mainly deriving from Senegal. Nine of them were previously sequenced for the E protein-
coding region and classified into different lineages (15), whereas 5 isolates were sequenced for the 
first time in this study and identified as lineage 4, based on the work of Sall et al. (15).  
Six of the sequenced strains (357, 6857, 6858, 6865, 6866, and 6867), all belonging to lineage 4, 
show heterogeneity in their virus population with an effect at the protein level. In all cases, the position 
is located in the E protein, which is known to be subjected to the highest selection pressure among all 
viral proteins.  
The newly sequenced isolates 6857, 6858, 6865, 6866, and 6867 revealed no differences within their 
genomes despite the diversity of vector hosts (Aedes furcifer, Aedes taylori, and Aedes 
luteocephalus), suggesting not only YFV genetic stability but also that one lineage (lineage 4) 
emerged in 2005. This lineage reemerges following its appearance from 1976 to 1979 and 2001, 
reinforcing the hypothesis that the different YFV lineages are enzootic in Kedougou and can emerge 
together or alternatively within Senegal or in West Africa (15).  
On closer examination of the amino acid sequence of the viral polyprotein, the YF isolates can clearly 
be assigned to the different lineages identified in advance (Figure 1). Regarding the amount of their 
differences compared to the reference strain Asibi, the strains are quite similar. Most striking is the 
large quantity of unique features of lineage 1 (strain 307) with 56.8% and lineage 3 (strains 333 and 
335) with 90%, quantified in relation to all amino acid differences from Asibi (Table 3).  
This divergence is especially marked for lineage 3 in terms of the deviating replication in the growth 
kinetics compared to the other strains analyzed in this study (see below) (Figure 7). The relevant 
mutations for lineage 3 accumulate in the proteins E, NS4B, and NS5.  
Whereas the E protein is the major envelope protein responsible for cell entry and membrane fusion 
(27), and thus subject to high selection pressure, NS4 and NS5 are nonstructural proteins functioning 
as components of the viral replication complex. The function and structure of the flaviviral NS4 protein 
are not yet fully understood. However, the NS4B subunit, in which lineage 3 shows four unique 
mutations, is most likely associated with the endoplasmic reticulum (ER) membrane and inhibits the 
interferon signaling pathway (28, 29).  
The structure and function of the flavivirus NS5 protein have further investigated (30, 31). The 
methyltransferase domain, which is essential for the mRNA capping process, lies in the N-terminal 
domain of the protein. Here we find two mutations of strain 333 (aa 2 and 258), which are located in 
the variable regions surrounding the conserved core region of the protein (aa 59 to 224).  
The residual C-terminal part of the NS5 protein comprises the RNA-dependent RNA polymerase 
domain (RdRp), exhibiting the typical finger, palm, and thumb subdomains of a polymerase and which 
is essential for de novo RNA synthesis and hence for viral replication. Within this domain, lineage 3 
shows four unique mutations (aa 335, 351, 660, and 878).  
Studies on dengue virus show that amino acids 335 and 351 are located within a region interacting 
with the NS3 protein and importin-β and thus functioning as a nuclear localization sequence (31). 
Even more striking is position 660, which is located within the active site of the palm subdomain, just 
adjacent to aa663, which has been shown to play a crucial role in the catalytic activity of the protein 
(31). This leads us to the assumption that these mutations could have an impact on the impaired 
growth behavior of this YFV strain in Ap61 cells.  
The 3′-NTR.The 3′-NTR of flaviviruses is known to develop a secondary structure which is considered 
to play an important role in viral replication and translation initiation (16, 32,–,34). Domain III, which 
lies at the very end of the 3′-NTR and forms a secondary structure known as the 3′ long stable hairpin 
(3′-LSH), is believed to build the functional core of the 3′-NTR (33, 34). In contrast, the domains 
between the stop codon and the 3′-LSH are much more divergent and seem to function as 
nonessential enhancer elements for replication, especially in the mammalian host (32, 35). Several 
studies focusing on the variability and the secondary structure of these domains (16, 32, 34) could 
identify hot spots of nucleotide variation (32) or wild isolates with large deletions or duplications (36) 
which did not affect the ability of the virus to replicate. Differences in pathogenicity between vaccine 
and wild-type strains could be traced back to an alternative folding of the 3′-LSH in domain III (33).  
Strain 307 (lineage 1) shows two exceptional mutations in the 3′-NTR compared to the other West 
African strains (Figure 3). One is an insertion just after the stop codon and the other is a deletion of 
170 bases farther downstream. Similar mutations have already been found in a strain also isolated in 
Ivory Coast, in relation to an outbreak in 1982 (25). As the secondary structure of this strain has 
already been elucidated and the unique deletion in strain 307 at position 3 lies in an area described as 
a hot spot of nucleotide variation (32), these mutations may not affect the secondary structure and the 
function of the 3′-NTR.  
The same applies for the mutations in the 3′-NTR observed for lineage 3. The mutations occur either 
in a hot spot of nucleotide variation (nucleotides 7 and 8), in the F3 loop of repeated sequence 1 
(RYF1) (nucleotide 54), which is known to be nonessential for viral replication, or in the Ish3 region of 
the 3′-LSH (nucleotide 449). The latter region lies within the functional core for viral replication but is 
known to accumulate mutations without an effect on stem formation (32).  
Phylogenetic analysis. The phylogenetic analyses, based on the full genome nucleotide sequences 
performed in this study, revealed a similar tree topology compared to the analyses based on E protein 
sequences for the West African YF strains (15). However, due to a restricted number of YFV isolates 
and full genome sequences, the possibilities to investigate the diversity and evolution of YFV in this 
study remain limited. Limitation is evident considering the subgroup of East and Central African 
genotypes of the Bayesian tree (Figure 2), where the YFV strains that have clearly been classified as 
independent genotypes in various studies (3, 11) appear here in a single clade. Further sampling and 
sequencing especially of East and Central African YFV wild isolates are necessary for a detailed 
division and could even uncover the existence of additional lineages, as shown here for the West 
African clade.  
In addition, monitoring of YFV distribution and evolution could strongly contribute to the understanding 
of the development of outbreaks and the complexity of viral zoonoses in general.  
The YF strain Trinidad79A is the only South America strain included in our phylogenetic analyses and 
is closely related to the Senegalese YF lineage 3. Previous studies by Chang et al. (13) on E protein 
sequences already suggested that this strain was a recent introduction from West Africa to Trinidad. In 
contrast, Wang et al. (16) classified this strain as derived from a South American genotype in their 
analyses of the 5′-NTR, the NS4 protein, and the 3′-NTR. Full genome sequencing of additional South 
American strains is needed to answer the question about the origin of the Trinidad79A strain.  
Two separate YF lineages are present in Ivory Coast, one clustering with the Senegalese lineage 6 
and the other one with lineage 1. This classification reflects a cocirculation of two different genotypes 
in Ivory Coast (West African genotypes I and II) or, due to the temporal separation of the isolations in 
1982 and 1999 (25, 37), a switch in circulation from West African genotype I to West African genotype 
II.  
Growth kinetics.To investigate the growth behavior of the different YF lineages circulating in Senegal, 
we performed growth kinetics on cells from the mosquito vector (Ap61) and human liver cells (HepG2). 
HepG2 cells have been used in several studies to investigate viral infections, especially of flaviviruses, 
and were thus chosen as the model cell line for our examinations (38,–,41). The aim of this 
experimental setup with the two cell lines was to cover the natural system of both the transmitting 
vector and the vertebrate host. We used the well-known prototype strain Asibi and the vaccine strain 
17D as reference strains.  
In human liver cells, the replication rates of the virus were similar for all strains. Differences were only 
revealed by microscopical observation, showing that the reference strains 17D and Asibi and isolate 
333 (lineage 3) are affecting the cells earlier than the other strains that were isolated from mosquitoes.  
Studies that compared the growth behavior of 17D and Asibi in HepG2 cells showed a higher 
susceptibility of the cells for the attenuated virus strain 17D within the first 3 days after infection (38). 
We also observed by IFA a lower infectivity of HepG2 cells with Asibi than that with 17D within 50 h 
postinfection. Nevertheless, the cells showed complete infection after 75 h for both strains (Table 4). In 
Ap61 cells, the contrary effect was observed by IFA, resulting in a lower infection of the cells with the 
strain 17D. All further analyzed parameters showed no difference in growth behavior between 17D and 
Asibi (Fig. 6 and 7).  
In insect cells, 17D and Asibi replicate much slower than the mosquito derived isolates (with the 
exception of strain 333), which probably could be explained by a poor uptake in the cells (Figure 7).  
The strain Asibi was isolated from a YF patient, and 17D arose from it through serial passaging (26). 
Both strains have been in laboratory use since their isolation in 1927 and the detailed passage history 
of many laboratory strains in use today is not always clear. Unlike these human isolates, all the other 
strains examined here originated from mosquitoes and have just a brief passage history mostly on 
insect cells. Hence, a previous adaptation to the appropriate host could be a possible explanation for 
the differential cellular damage of these strains in the insect and human cells in our study.  
In nature, YFV always switches between insect vector and primate without apparent adaptation to one 
of these hosts and the genetic stability of the virus has consistently been confirmed by many studies 
(3, 11, 14, 17).  
A study by Cooper and Scott (42) demonstrates that these ideas do not necessarily have to be 
contradictory. They could show that strains of eastern equine encephalitis virus (EEEV), which have 
been cultivated by alternating passaging between insect and avian cells, exhibited a higher virion 
production in both cell lines than strains that have been cultivated in only one cell type. Furthermore, 
EEEV strains that have been adapted to insect cells showed an increased susceptibility to insect cells, 
whereas strains adapted to avian cells showed unimproved growth in both cell lines. These results 
indicated that alternating hosts select for virus populations that are able to replicate well in both 
systems.  
In both cell lines, strain 333 (lineage 3) presented distinctive behavior. In human liver cells, it is 
surprising that the growth of strain 333 more closely resembles that of the reference strains isolated 
from YF patients than that of the other mosquito isolates.  
Moreover, this lineage is the only one that could be linked with vertical transmission in nature until now 
(15). Also in this case, strain 333 was isolated from a male mosquito or a female neonate, thus arising 
from vertical transmission. In our study, this strain did not replicate efficiently in Ap61 cells (Figure 4c 
and 7), which are derived from Aedes pseudoscutellaris larvae. Vertical transmission and persistence 
in mosquito eggs is a mechanism of long-time survival or rather a maintenance mechanism of the 
virus. At this stage, only minimal cell metabolism is detectable in insect cells. Our experiments did not 
show clear replication activity by plaque assay, PCR, or IFA, but we observed early cellular damage 
due to virus infection. As viral replication relies on the replication machinery of the host cell, early 
cellular damage probably caused the stagnating growth curve observed in our analysis. How this 
coincides with the adaptation of the virus to mosquito cells or with the maintenance mechanism of 
vertical transmission remains to be elucidated.  
Taking these observations into account, together with the sequence differences in the viral polyprotein 
compared to all the other strains, a further analysis of this lineage would be very interesting for the 
investigation of certain protein functions and for the understanding of vertical transmission.  
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Tables and Figures 
Table 1. Isolates of YFV analyzed in this study 
 
a
 Collected from male mosquitoes or female neonates. 
 





Table 3. Amounts of amino acid differences of the various YFV lineages compared to Asibi over the 
whole coding region 
 
a
 Number of unique mutations that occur only in the indicated lineage. Percentages reflect the 
proportion of unique features for each lineage relative to the total number of aa differences from Asibi. 
Table 4. Results of the immunofluorescence assay of Ap61 and HepG2 cells infected with the different 





 Infection was visualized by fluorescence staining against the viral E protein, and results are given as 
percentages. Estimated percentages of infection are indicated as follows: (+), 
<10%; +, 10 to 40%; +(+), 40 to 50%; ++, 50 to 75%; ++(+), 75 to 85%; +++, 85 to 100%. A minus 
indicates no infection or a negative result.  
Figure 1. Differences in the amino acid sequence throughout the viral polyprotein among the YFV 
strains that were completely sequenced in this study in comparison to the reference strain Asibi. 





Figure 2. Majority rule consensus tree of the Bayesian analysis, with 10 million generations based on 
YFV full genome sequences. Posterior probability values are displayed beside the related node. 
Bootstrap values of the ML analysis are given in parentheses. Note that unsupported values of 50/0.5 
or less are indicated by a minus sign. The appropriate lineages of the already classified YF strains are 





Figure 3. RNA sequence alignment of the 3′-nontranslated region (3′-NTR) of 18 West African YFV 






Figure 4. Growth kinetics of the strains Asibi (a), 357 (lineage 4) (b), and 333 (lineage 3) (c). The 
diagrams show the amount of viral RNA equivalents isolated from supernatants (•) and cells (■) 
(genome equivalents [GE]/ml), as well as the number of infectious viral particles (▲) (PFU/ml) over a 
time period of 146 h postinfection. The experiments were performed with Ap61 cells (dotted lines) and 
HepG2 cells (continuous lines). Range values of two independent experiments are indicated by the 





Figure 5. Immunofluorescence assay of Ap61 and HepG2 cells infected with YFV Asibi or YFV 357 
within a time period of 50 to 146 h postinfection. Staining occurred against the viral E protein 
(MAK6330) and the nucleus (DAPI) as described above.  
 
  
Figure 6. Growth curves of the different YF lineages in HepG2 cells. Analyzed parameters are the 
quantity of viral RNA copies isolated from cell culture supernatants (a) and from cells directly (b) 
(GE/ml) and the quantity of infectious viral particles (c) (PFU/ml). Range values of two independent 
experiments are indicated by the error bars in panel a.  
 
  
Figure 7. Growth curves of all tested strains determined with Ap61 cells. Analyzed parameters are the 
quantity of viral RNA copies isolated from cell culture supernatants (a) and from cells (b) (GE/ml) and 
the quantity of infectious viral particles (c) (PFU/ml). Range values of two independent experiments 
are indicated by the error bars in panel a.  
 
